Literature DB >> 27183601

Intravaginal Zinc Oxide Tetrapod Nanoparticles as Novel Immunoprotective Agents against Genital Herpes.

Thessicar E Antoine1, Satvik R Hadigal2, Abraam M Yakoub1, Yogendra Kumar Mishra3, Palash Bhattacharya4, Christine Haddad4, Tibor Valyi-Nagy5, Rainer Adelung3, Bellur S Prabhakar4, Deepak Shukla6.   

Abstract

Virtually all efforts to generate an effective protection against the life-long, recurrent genital infections caused by HSV-2 have failed. Apart from sexual transmission, the virus can also be transmitted from mothers to neonates, and it is a key facilitator of HIV coacquisition. In this article, we uncover a nanoimmunotherapy using specially designed zinc oxide tetrapod nanoparticles (ZOTEN) with engineered oxygen vacancies. We demonstrate that ZOTEN, when used intravaginally as a microbicide, is an effective suppressor of HSV-2 genital infection in female BALB/c mice. The strong HSV-2 trapping ability of ZOTEN significantly reduced the clinical signs of vaginal infection and effectively decreased animal mortality. In parallel, ZOTEN promoted the presentation of bound HSV-2 virions to mucosal APCs, enhancing T cell-mediated and Ab-mediated responses to the infection, and thereby suppressing a reinfection. We also found that ZOTEN exhibits strong adjuvant-like properties, which is highly comparable with alum, a commonly used adjuvant. Overall, to our knowledge, our study provides the very first evidence for the protective efficacy of an intravaginal microbicide/vaccine or microbivac platform against primary and secondary female genital herpes infections.
Copyright © 2016 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27183601      PMCID: PMC4875784          DOI: 10.4049/jimmunol.1502373

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  34 in total

Review 1.  Multifunctional nanoparticles--properties and prospects for their use in human medicine.

Authors:  Nuria Sanvicens; M Pilar Marco
Journal:  Trends Biotechnol       Date:  2008-08       Impact factor: 19.536

2.  Efficacy results of a trial of a herpes simplex vaccine.

Authors:  Robert B Belshe; Peter A Leone; David I Bernstein; Anna Wald; Myron J Levin; Jack T Stapleton; Iris Gorfinkel; Rhoda L Ashley Morrow; Marian G Ewell; Abbie Stokes-Riner; Gary Dubin; Thomas C Heineman; Joann M Schulte; Carolyn D Deal
Journal:  N Engl J Med       Date:  2012-01-05       Impact factor: 91.245

Review 3.  Herpes simplex virus infections.

Authors:  R J Whitley; B Roizman
Journal:  Lancet       Date:  2001-05-12       Impact factor: 79.321

4.  Safety and immunogenicity of glycoprotein D-adjuvant genital herpes vaccine.

Authors:  David I Bernstein; Fred Y Aoki; Stephen K Tyring; Lawrence R Stanberry; Claude St-Pierre; Stephen D Shafran; Geert Leroux-Roels; Koen Van Herck; Anne Bollaerts; Gary Dubin
Journal:  Clin Infect Dis       Date:  2005-03-24       Impact factor: 9.079

5.  Double-blind, placebo-controlled trial of a herpes simplex virus type 2 glycoprotein vaccine in persons at high risk for genital herpes infection.

Authors:  G J Mertz; R Ashley; R L Burke; J Benedetti; C Critchlow; C C Jones; L Corey
Journal:  J Infect Dis       Date:  1990-04       Impact factor: 5.226

6.  Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile.

Authors:  Jeffrey Hrkach; Daniel Von Hoff; Mir Mukkaram Ali; Elizaveta Andrianova; Jason Auer; Tarikh Campbell; David De Witt; Michael Figa; Maria Figueiredo; Allen Horhota; Susan Low; Kevin McDonnell; Erick Peeke; Beadle Retnarajan; Abhimanyu Sabnis; Edward Schnipper; Jeffrey J Song; Young Ho Song; Jason Summa; Douglas Tompsett; Greg Troiano; Tina Van Geen Hoven; Jim Wright; Patricia LoRusso; Philip W Kantoff; Neil H Bander; Christopher Sweeney; Omid C Farokhzad; Robert Langer; Stephen Zale
Journal:  Sci Transl Med       Date:  2012-04-04       Impact factor: 17.956

7.  The gH-gL complex of herpes simplex virus (HSV) stimulates neutralizing antibody and protects mice against HSV type 1 challenge.

Authors:  T Peng; M Ponce-de-Leon; H Jiang; G Dubin; J M Lubinski; R J Eisenberg; G H Cohen
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

8.  An investigative peptide-acyclovir combination to control herpes simplex virus type 1 ocular infection.

Authors:  Paul J Park; Thessicar E Antoine; Asim V Farooq; Tibor Valyi-Nagy; Deepak Shukla
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-09-27       Impact factor: 4.799

Review 9.  Nanoparticle therapeutics: an emerging treatment modality for cancer.

Authors:  Mark E Davis; Zhuo Georgia Chen; Dong M Shin
Journal:  Nat Rev Drug Discov       Date:  2008-09       Impact factor: 84.694

10.  Alum induces innate immune responses through macrophage and mast cell sensors, but these sensors are not required for alum to act as an adjuvant for specific immunity.

Authors:  Amy S McKee; Michael W Munks; Megan K L MacLeod; Courtney J Fleenor; Nico Van Rooijen; John W Kappler; Philippa Marrack
Journal:  J Immunol       Date:  2009-09-04       Impact factor: 5.422

View more
  37 in total

1.  Nanostructured Fibrous Membranes with Rose Spike-Like Architecture.

Authors:  Amir Nasajpour; Serena Mandla; Sindu Shree; Ebrahim Mostafavi; Roholah Sharifi; Akbar Khalilpour; Saghi Saghazadeh; Shabir Hassan; Michael J Mitchell; Jeroen Leijten; Xu Hou; Alireza Moshaverinia; Nasim Annabi; Rainer Adelung; Yogendra Kumar Mishra; Su Ryon Shin; Ali Tamayol; Ali Khademhosseini
Journal:  Nano Lett       Date:  2017-09-18       Impact factor: 11.189

Review 2.  Phytosynthesized metal oxide nanoparticles for pharmaceutical applications.

Authors:  Swetha Andra; Satheesh Kumar Balu; Jaison Jeevanandham; Murugesan Muthalagu; Manisha Vidyavathy; Yen San Chan; Michael Kobina Danquah
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-05-17       Impact factor: 3.000

3.  Impact of Type I Interferon on the Safety and Immunogenicity of an Experimental Live-Attenuated Herpes Simplex Virus 1 Vaccine in Mice.

Authors:  Derek J Royer; Meghan M Carr; Ana J Chucair-Elliott; William P Halford; Daniel J J Carr
Journal:  J Virol       Date:  2017-03-13       Impact factor: 5.103

Review 4.  Vaginal delivery of vaccines.

Authors:  Hannah M VanBenschoten; Kim A Woodrow
Journal:  Adv Drug Deliv Rev       Date:  2021-09-01       Impact factor: 15.470

Review 5.  Role of metal and metal oxide nanoparticles as diagnostic and therapeutic tools for highly prevalent viral infections.

Authors:  Tejabhiram Yadavalli; Deepak Shukla
Journal:  Nanomedicine       Date:  2016-08-26       Impact factor: 5.307

Review 6.  A Critical Review of the Use of Surfactant-Coated Nanoparticles in Nanomedicine and Food Nanotechnology.

Authors:  Taiki Miyazawa; Mayuko Itaya; Gregor C Burdeos; Kiyotaka Nakagawa; Teruo Miyazawa
Journal:  Int J Nanomedicine       Date:  2021-06-09

Review 7.  Potential applications of engineered nanoparticles in medicine and biology: an update.

Authors:  Gudepalya Renukaiah Rudramurthy; Mallappa Kumara Swamy
Journal:  J Biol Inorg Chem       Date:  2018-08-10       Impact factor: 3.862

8.  Effects of Zinc Oxide Nanoparticles on Growth, Intestinal Barrier, Oxidative Status and Mineral Deposition in 21-Day-Old Broiler Chicks.

Authors:  Jiaqi Zhang; Caiyun Yu; Zhihua Li; Jian Li; Yueping Chen; Tian Wang; Chao Wang
Journal:  Biol Trace Elem Res       Date:  2021-06-08       Impact factor: 3.738

Review 9.  Use of nanotechnology in combating coronavirus.

Authors:  Saee Gharpure; Balaprasad Ankamwar
Journal:  3 Biotech       Date:  2021-06-28       Impact factor: 2.406

10.  Sensitive Metal Oxide-Clay Nanocomposite Colorimetric Sensor Development for Aflatoxin Detection in Foods: Corn and Almond.

Authors:  Nishtha Khansili; Prayaga Murali Krishna
Journal:  ACS Omega       Date:  2021-06-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.